Inclusion Criteria:

          -  Histologically or cytologically confirmed solid tumors with evidence of metastatic or
             locally disease not amenable to standard therapy with curative intent with patients
             with metastatic colorectal cancer treated in the metastatic setting with standard
             approved therapy including oxaliplatin, irinotecan and fluoropyrimidines (5-FU and/or
             capecitabine) ± an anti-angiogenic agent ± an anti-EGFR agent.

          -  A baseline fresh tumor sample (FFPE and if sufficient material also frozen) from a
             metastatic or primary site.

          -  Measurable disease as defined by RECIST version 1.1 by radiologic methods.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Life expectancy ≥ 12 weeks, as per investigator.

          -  Adequate organ function

        Exclusion Criteria:

          -  Central nervous system metastases that are untreated or symptomatic, or require
             radiation, surgery, or continued steroid therapy to control symptoms within 14 days of
             study entry.

          -  Known leptomeningeal involvement.

          -  Participation in another clinical trial or treatment with any investigational drug
             within 4 weeks prior to study entry.

          -  Any systemic anticancer therapy within 4 weeks or 5 half-lives whichever is longer of
             the first dose of study treatment. For cytotoxic agents that have major delayed
             toxicity ( e.g. mitomycin C,nitrosoureas), or anticancer immunotherapies, a washout
             period of 6 weeks is required.

          -  Requirement for immunosuppressive medication (e.g. methotrexate, cyclophosphamide)

          -  Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.
             Patients who received prior radiotherapy to ≥25% of bone marrow are not eligible,
             irrespective of when it was received.

          -  Persistent grade >1 clinically significant toxicities related to prior antineoplastic
             therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 NCI-CTCAE v4.03
             is allowed.

          -  History of hypersensitivity reaction or any toxicity attributed to human proteins or
             any of the excipients that warranted permanent cessation of these agents.

          -  Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg) with
             appropriate treatment or unstable angina.

          -  History of congestive heart failure of Class II-IV New York Heart Association (NYHA)
             criteria, or serious cardiac arrhythmia requiring treatment (except atrial
             fibrillation, paroxysmal supraventricular tachycardia).

          -  History of myocardial infarction within 6 months of study entry.

          -  History of prior malignancies with the exception of excised cervical intraepithelial
             neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk
             for recurrence with no evidence of disease for at least 3 years.

          -  Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen
             therapy.

          -  Patients with a history of interstitial lung disease (e.g.: pneumonitis or pulmonary
             fibrosis) or evidence of ILD on baseline chest CT scan.

          -  Current serious illness or medical conditions including, but not limited to
             uncontrolled active infection,clinically significant pulmonary, metabolic or
             psychiatric disorders.

          -  Active HIV, HBV, or HCV infection requiring specific treatment.

          -  Pregnant or lactating women; patients of childbearing potential must use highly
             effective contraception methods prior to study entry, for the duration of study
             participation, and for 6 months after the last dose of MCLA-158.